Results of a Phase 2 Study of Pacritinib (SB1518), a JAK2/JAK2(V617F) Inhibitor, in Patients With Myelofibrosis
Blood - United States
doi 10.1182/blood-2013-02-484832
Full Text
Open PDFAbstract
Available in full text
Date
April 23, 2015
Authors
Publisher
American Society of Hematology